AstraZeneca’s newest asthma launch fills a gap as generics chip away at respiratory flagships

A longtime leader in the respiratory space, AstraZeneca has hammered another stake in the ground with its newest asthma treatment, Airsupra.

By Michael Gibney • Jan. 24, 2023

Drug price negotiations: 5 key dates to watch

As the CMS readies its new program for lowering drug costs, these are the moments that will matter most to pharma companies.

By Kelly Bilodeau • Jan. 23, 2023

Already on a roll in oncology, Astellas hunts for big wins in other areas

With two potential first-in-class drug launches on the horizon, and a budding gene therapy business, Astellas believes this year could be a major inflection point. 

By Karissa Waddick • Jan. 23, 2023

Tactics for growing your walled garden presence

Cultivate relationships with HCPs in gated social platforms with content that will thrive.

Jan. 23, 2023

FDA’s 2022 drug approvals fall short of recent norms

The U.S. agency’s lower number of novel drug approvals followed several controversies surrounding a 2021 Alzheimer’s approval.

By Alexandra Pecci • Jan. 19, 2023

After ‘limping along,’ Novavax sees a path forward

With a new CEO and a long-term booster strategy, the company believes there’s plenty of room to grow in the COVID-19 vaccine space.

By Meagan Parrish • Jan. 18, 2023

Can pharma quit Twitter? Social strategy evolves as Musk changes the platform

A breakdown of how Twitter’s recent shifts are impacting pharma, and how the industry should navigate the platform in 2023.

By Karissa Waddick • Dec. 16, 2022

Woman of the Week: Exelixis’ Dr. Vicki Goodman

With several blockbuster products under her belt, veteran oncologist and drug developer Dr. Vicki Goodman is looking to further evolve Exelixis’ pipeline to address hard-to-treat cancers.

By Taren Grom • Dec. 14, 2022

Dr. Sy Pretorius, Eversana’s new COO, is flipping the script on his career

With a long history in the clinical space, Pretorius is now applying those deep insights to the commercial side of the business.

By Taren Grom • Dec. 9, 2022

An FDA proposal could make OTC switches easier. Here’s what the industry has to say

How the FDA’s proposal to create a new OTC approval pathway could impact the pharma industry.

By Karissa Waddick • Dec. 5, 2022

Executive changes at Teva, Eversana could spell commercial growth in the new year

With their latest personnel moves, these life sciences companies are preparing for major business shifts.

By Karissa Waddick • Nov. 23, 2022

4 pioneering social media campaigns in pharma this year

The key to a great social media campaign is often simplicity, and these pharma companies hit the nail on the head with unique strategies that aim to educate. 

By Karissa Waddick • Nov. 17, 2022

While DCTs get all the hype, some industry insiders say the future is a digital hybrid

Leaders at Veeva believe the wording around decentralized trials has been exaggerated, and that a bigger-picture outlook is important as the pandemic winds down.

By Michael Gibney • Nov. 1, 2022

Woman of the Week: Ironwood Pharmaceuticals’ Diane Stroehmann

The VP of regulatory affairs and global patient safety explains why her line of work lets her do “a little of everything,” and the company’s plans to score a new approval for its blockbuster drug.

By Taren Grom • Oct. 26, 2022

Backed by celebrity interest, Novo is finding new success in weight loss — while staying true to its roots

The company's head of U.S. and Canadian operations explains how it’s evolving its game plan after 100 years in the insulin space.

By Meagan Parrish • Oct. 25, 2022

Biosimilars will gain ground in 2023 with Humira launches — and that’s just the beginning

In Amgen's 2022 Biosimilars Trend Report, the company tracks the progress and potential of the copycat drugs as they reach a pivotal moment.

By Michael Gibney • Oct. 24, 2022

Think your company could be on HHS’ drug price negotiation list? Here’s how to navigate next steps

Know what to expect from the CMS over the next few months as it implements the drug reforms laid out in the Inflation Reduction Act.

By Karissa Waddick • Oct. 18, 2022

Citius Pharmaceuticals sees golden opportunities in late-stage specialty assets

CEO Leonard Mazur explains how the company’s hoping to unlock the potential of its varied pipeline.

By Karissa Waddick • Oct. 11, 2022

Her antibiotic company failed. Now she’s helping others avoid the same fate.

The chief of R&D at CARB-X explains why she believes small antibiotics companies can succeed despite market turmoil.

By Karissa Waddick • Oct. 6, 2022

C-suite shake-ups at 23andMe, Moderna signal new stages of growth

With their latest personnel moves, these life sciences companies are preparing for major business shifts.

By Karissa Waddick • Oct. 5, 2022

Compass has the most advanced psychedelic drug in trials — but it needs a new approach to rollout to make it a success

The company's CEO, Kabir Nath, discusses potential roadblocks to commecialization that await its psilocybin treatment for depression. 

By Meagan Parrish • Sept. 27, 2022

3 keys to value for unlocking the promise of cell therapies

There is no question about the incredible clinical impact cell therapies can have on the lives of patients. However, this impact is the result of innovation that does not equate to a simple, straightforward commercialization process.

Sept. 26, 2022

Woman of the Week: Foresite Capital’s Cindy Mesaros

The longtime marketing pro details her fascinating career journey and how she’s positioning early stage health companies to thrive. 

By Taren Grom • Sept. 7, 2022

Moderna’s lawsuit against Pfizer and BioNTech explained in 10 quotes

The biotech says that its competitors’ COVID-19 vaccine copied proprietary mRNA technology. Here’s a breakdown of the case.

By Karissa Waddick • Aug. 31, 2022

Hurdles remain in biosims market — but Alvotech is undeterred

The biosimilar developer is advancing a pipeline with high growth potential, including a copycat of Humira.

By Kelly Bilodeau • Aug. 29, 2022